GlassScriptPhysician profile
Marilizabeth Birk
NPI 1306453220
$33,679.33
in general payments reported to CMS, 2019-2025
17 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $434 · 2023: $1,965 · 2024: $3,221 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $11K · Travel and Lodging: $4,867 · Consulting Fee: $2,410 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,100.00 |
| Food and Beverage | $10,706.72 |
| Travel and Lodging | $4,867.02 |
| Consulting Fee | $2,410.00 |
| Education | $161.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,502.54 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,707.39 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $1,713.26 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,480.80 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $1,362.32 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,262.28 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $839.79 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $513.56 | 2022-2025 | Ingrezza |
| Janssen Scientific Affairs, LLC | $348.31 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $298.42 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $233.16 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $199.37 | 2024 | Qelbree |
| Corium, LLC | $89.61 | 2025 | Azstarys |
| Celgene Corporation | $54.90 | 2025 | Cobenfy |
| Tris Pharma INC | $39.01 | 2025 | Dyanavel Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.15 | 2022 | |
| Luye Pharma (USA) LTD. | $16.46 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilizabeth Birk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.